In 2026, the life sciences industry reached its strictest compliance turning point. Medical anti-corruption is no longer limited to verbal rectification or simple fines. It has officially entered the stage of criminal accountability. Starting May 1 this year, improper economic dealings with hospitals and physicians directly touch the criminal red line. The former hidden rules have all become high-voltage lines, and the business logic of the entire industry has been rewritten.
Many people think anti-corruption is far away from them. In fact, the new rules lower the threshold to a level ordinary people can understand:
- If a physician accumulates RMB 30,000 in kickbacks or improper benefits, it constitutes a crime.
- If a medical representative offers RMB 100,000 in bribes, it constitutes bribery of non-state personnel and may face criminal punishment.
- If a pharmaceutical company offers RMB 200,000 in bribes as an organization, not only will the company be heavily punished, but owners and executives will also bear responsibility.
- More importantly, the old path of shifting responsibility through outsourced companies or individual names no longer works. As long as the money comes from the company and the profit returns to the company, accountability can penetrate through any number of outsourcing layers. There is no room for luck.
Common industry practices from the past are now all high risk: giving physicians gift cards, arranging travel, or hosting luxury banquets is not acceptable; nominal lectures or consulting without real work and with inflated fees are directly treated as bribery; even small gifts given repeatedly can be accumulated in amount, and retirement or resignation cannot avoid accountability. Old methods such as offline visits and private relationship maintenance have completely failed. Hospital controls are becoming stricter, appointments, records, and limited-time communication are becoming normal, zero tolerance applies to private benefit exchanges, and the traditional relationship model has reached its end.
For pharmaceutical companies, medical device companies, and hospital service providers, the biggest current challenge is this: the old road is blocked, so where is the new road? Without kickbacks, gifts, or relationship-based influence, how can companies build normal professional connections with physicians and experts? Academic meetings still need to be held, experts still need to cooperate, and the industry still needs communication, but every step risks crossing a line. Speaker fees and meeting sponsorships can touch red lines if handled carelessly. Compliance has become a line between survival and failure.
The core of industry transformation is shifting from relationship-driven to professional compliance-driven, with digital intelligence tools becoming the key lever. MeDomino has long focused on life sciences, covering pharmaceuticals, medical devices, and other scenarios. Targeting compliance marketing pain points in life sciences, MeDomino has built HCP360 and a compliant speaker verification system to help companies leave traditional relationship thinking behind and follow a compliant academic path.
HCP360 is based on compliant public data for healthcare professionals and builds panoramic physician profiles. Without relying on private inquiries or relationship maintenance, companies can accurately understand physicians' academic directions, professional fields, interests, preferences, and cooperation tendencies. Companies no longer need to blindly visit hospitals and depend on luck. Instead, they can use professional data matching to find truly suitable academic partners and focus energy on professional exchange and academic value delivery, making work both compliant and efficient.
For high-risk compliance areas such as speaker fees and academic meetings, the compliant speaker verification system controls risk from the source. It verifies experts' real academic qualifications, matches lecture content with professional fields, ensures every academic activity has real academic support and full traceable records, prevents false cooperation and inflated speaker fees, and helps companies turn academic activities into compliant professional exchange rather than a cover for benefit transfer.
Today's life sciences industry is no longer an era of relying on relationships or competing on spending. Judicialized anti-corruption has turned compliance from a slogan into a hard bottom line. Any opportunistic or lucky approach will eventually pay a heavy price. Whether the company is in pharmaceuticals, devices, medical aesthetics, or hospital-related services, only by fully leaving the rough old model behind, embracing compliance, deepening professionalism, and using digital intelligence tools to build a healthy academic cooperation system can it stand firm and go further in the new industry cycle.
Compliance is not a constraint, but a shield for healthy industry development. Leaving old routines behind and embracing new rules is the inevitable choice for every practitioner.
Compliance Statement:
The legal descriptions in this article are strictly based on the original text of the Interpretation II on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery, issued by the Supreme People's Court and the Supreme People's Procuratorate on April 10, 2026. The industry analysis is based on public developments and objective observation, and does not constitute legal advice or a business commitment. If there is any infringement or misunderstanding, please contact us promptly.
Reference Materials:
Information Bureau of the Supreme People's Court: The Supreme People's Court and the Supreme People's Procuratorate issued the Interpretation II on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery https://www.court.gov.cn/fabu/xiangqing/497181.html
